Gleason Group
RNTX icon

Gleason Group’s Rein Therapeutics RNTX Stock Holding History

Gleason Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18K Hold
22,389
– – ﹤0.01% 172
2026
Q2 		$23.3K Hold
22,389
– – ﹤0.01% 171
2026
Q1 		$29.1K Hold
22,389
– – ﹤0.01% 144
2025
Q4 		$26K Hold
22,389
– – ﹤0.01% 146
2025
Q3 		$25.6K Hold
22,389
– – ﹤0.01% 134
2025
Q2 		$31.3K Buy
+22,389
New +$40.3K ﹤0.01% 130

Other funds holding RNTX

Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Americana Partners
Americana Partners Houston, Texas $4.67B AUM 26.97% 1-Year Est. Return
SteelPeak Wealth
SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
Chicago Partners Investment Group
Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return
Sanders Morris Harris
Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return
Cane Capital Partners
Cane Capital Partners Saint Francisville, Louisiana $269M AUM 28.65% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

Gleason Group's RNTX Position: Q3 2026 in Review

Gleason Group held its Rein Therapeutics (RNTX) position steady in Q3 2026 at 22,389 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #172.

Gleason Group first reported a position in RNTX in Q2 2025 and has held it in 6 quarters since. The position peaked at $31.3K in Q2 2025. 12 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

  • Gleason Group held 22,389 shares of Rein Therapeutics worth $18K as of Q3 2026.
  • Gleason Group left its Rein Therapeutics share count unchanged in Q3 2026.
  • Rein Therapeutics made up ﹤0.01% of Gleason Group's portfolio in Q3 2026, its #172 holding.
  • Gleason Group first reported a position in Rein Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Gleason Group's Rein Therapeutics position peaked at $31.3K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on Gleason Group's 13F filing for Q3 2026, filed 15 Oct 2026.